U.S. markets closed

Biohaven Ltd. (BHVN)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
53.08-0.41 (-0.77%)
Al cierre: 04:00PM EDT
52.00 -1.08 (-2.03%)
Fuera de horario: 06:53PM EDT

Biohaven Ltd.

215 Church Street
New Haven, CT 06510
United States
203 404 0410
https://www.biohaven.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo239

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Vladimir Coric M.D.Chairman & CEO1.96MN/D1971
Mr. Matthew ButenChief Financial Officer1.05MN/D1961
Dr. Bruce D. Car DACVP, Ph.D.Chief Scientific Officer883.03kN/D1962
Ms. Kimberly GentileSenior Vice President of Clinical Operations858.65kN/D1966
Ms. Deb YoungDirector of Regulatory Affairs & OperationsN/DN/DN/D
Mr. George C. ClarkVP & Chief Accounting OfficerN/DN/D1984
Ms. Jennifer PorcelliVice President of Investor RelationsN/DN/DN/D
Mr. Warren Volles J.D.General Counsel & Chief Legal OfficerN/DN/DN/D
Mr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerN/DN/DN/D
Mr. John TiltonChief Commercial Officer of Rare DiseasesN/DN/D1968
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Gestión corporativa

La calificación ISS Governance QuickScore de Biohaven Ltd. a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 1; Junta: 8; Derechos del accionista: 3; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.